These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30607789)

  • 61. [Cancer causes: what levers for primary prevention?].
    Vidican P; Dussart S; Perol O; Praud D; Fervers B
    Rev Prat; 2024 Jan; 74(1):36-39. PubMed ID: 38329249
    [TBL] [Abstract][Full Text] [Related]  

  • 62. European Code against Cancer 4th Edition: Process of reviewing the scientific evidence and revising the recommendations.
    Minozzi S; Armaroli P; Espina C; Villain P; Wiseman M; Schüz J; Segnan N
    Cancer Epidemiol; 2015 Dec; 39 Suppl 1():S11-9. PubMed ID: 26439654
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive Cardiology.
    Joshi PH; Chaudhari S; Blaha MJ; Jones SR; Martin SS; Post WS; Cannon CP; Fonarow GC; Wong ND; Amsterdam E; Hirshfeld JW; Blumenthal RS
    Clin Cardiol; 2012; 35(7):404-9. PubMed ID: 22674150
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Etiologic evidence and primary prevention of cancer.
    Tomatis L
    Drug Metab Rev; 2000 May; 32(2):129-37. PubMed ID: 10774769
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Study protocol for a systematic review of evidence for lifestyle interventions targeting smoking, sleep, alcohol/other drug use, physical activity, and healthy diet in people with bipolar disorder.
    Kay-Lambkin FJ; Thornton L; Lappin JM; Hanstock T; Sylvia L; Jacka F; Baker AL; Berk M; Mitchell PB; Callister R; Rogers N; Webster S; Dennis S; Oldmeadow C; MacKinnon A; Doran C; Turner A; Hunt S
    Syst Rev; 2016 Jul; 5(1):106. PubMed ID: 27381332
    [TBL] [Abstract][Full Text] [Related]  

  • 66. European Code against Cancer 4th Edition: Infections and Cancer.
    Villain P; Gonzalez P; Almonte M; Franceschi S; Dillner J; Anttila A; Park JY; De Vuyst H; Herrero R
    Cancer Epidemiol; 2015 Dec; 39 Suppl 1():S120-38. PubMed ID: 26589774
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The research and development agenda for cancer prevention and education in Australia.
    Owen N; Hiller J; Woodward A
    Asia Pac J Public Health; 1991; 5(3):249-55. PubMed ID: 1823810
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effectiveness of programmes as part of primary prevention demonstrated on the example of cardiovascular diseases and the metabolic syndrome.
    Korczak D; Dietl M; Steinhauser G
    GMS Health Technol Assess; 2011 Apr; 7():Doc02. PubMed ID: 21468290
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Physical activity in basic and primary prevention of cardiovascular disease].
    Sobieszczańska M; Kałka D; Pilecki W; Adamus J
    Pol Merkur Lekarski; 2009 Jun; 26(156):659-64. PubMed ID: 19711738
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pathways Forward in Cardiovascular Disease Prevention One and a Half Years After Publication of the 2013 ACC/AHA Cardiovascular Disease Prevention Guidelines.
    Cainzos-Achirica M; Desai CS; Wang L; Blaha MJ; Lopez-Jimenez F; Kopecky SL; Blumenthal RS; Martin SS
    Mayo Clin Proc; 2015 Sep; 90(9):1262-71. PubMed ID: 26269108
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pediatric lipid management: an earlier approach.
    Zachariah JP; Johnson PK
    Endocrinol Metab Clin North Am; 2014 Dec; 43(4):981-92. PubMed ID: 25432392
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019).
    Majem M; García-Martínez E; Martinez M; Muñoz-Couselo E; Rodriguez-Abreu D; Alvarez R; Arance A; Berrocal A; de la Cruz-Merino L; Lopez-Martin JA
    Clin Transl Oncol; 2020 Feb; 22(2):213-222. PubMed ID: 31993963
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SEOM clinical guidelines for the treatment of metastatic breast cancer.
    Alvarez López I; de la Haba Rodríguez J; Ruiz Simón A; Bellet Ezquerra M; Calvo Martínez L; García Estévez L; Rodríguez Lescure Á; Isla Casado D;
    Clin Transl Oncol; 2010 Nov; 12(11):719-23. PubMed ID: 20974562
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cancers related to lifestyle and environmental factors in France in 2015.
    Soerjomataram I; Shield K; Marant-Micallef C; Vignat J; Hill C; Rogel A; Menvielle G; Dossus L; Ormsby JN; Rehm J; Rushton L; Vineis P; Parkin M; Bray F
    Eur J Cancer; 2018 Dec; 105():103-113. PubMed ID: 30445359
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Modifiable Lifestyle Factors for Primary Prevention of CKD: A Systematic Review and Meta-Analysis.
    Kelly JT; Su G; Zhang L; Qin X; Marshall S; González-Ortiz A; Clase CM; Campbell KL; Xu H; Carrero JJ
    J Am Soc Nephrol; 2021 Jan; 32(1):239-253. PubMed ID: 32868398
    [TBL] [Abstract][Full Text] [Related]  

  • 76. SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).
    González-Santiago S; Ramón Y Cajal T; Aguirre E; Alés-Martínez JE; Andrés R; Balmaña J; Graña B; Herrero A; Llort G; González-Del-Alba A;
    Clin Transl Oncol; 2020 Feb; 22(2):193-200. PubMed ID: 31889241
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Primary prevention of cancer and cardiovascular diseases: an overview of scientific literature].
    Faggiano F; Concina D; Molinar R; Allara E
    Epidemiol Prev; 2014; 38(6 Suppl 2):19-22. PubMed ID: 25759338
    [TBL] [Abstract][Full Text] [Related]  

  • 79. SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018).
    González Del Alba A; De Velasco G; Lainez N; Maroto P; Morales-Barrera R; Muñoz-Langa J; Pérez-Valderrama B; Basterretxea L; Caballero C; Vazquez S
    Clin Transl Oncol; 2019 Jan; 21(1):64-74. PubMed ID: 30565086
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Presenting Benefits and Downsides to Facilitate High-Quality Decision-Making About Cancer Screening.
    Pignone M
    J Natl Cancer Inst; 2016 Jun; 108(6):djv433. PubMed ID: 26917629
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.